uniQure Reports GAAP EPS of -$1.22, Revenue Beats Estimates
uniQure (NASDAQ: QURE) reported second-quarter results with a GAAP earnings per share (EPS) loss of $1.22, which missed estimates by $0.42. However, the company's revenue came in at $5.84 million, surpassing expectations by $0.46 million and showing an 11% year-over-year increase. The mixed results highlight both challenges and progress for uniQure as it continues to develop its gene therapy pipeline. The strong revenue growth suggests some momentum despite the earnings miss. Investors are likely watching closely how these financials align with regulatory developments, particularly around AMT-130, a key candidate in their portfolio. The company's recent news about FDA-related updates has previously driven stock volatility and investor interest, indicating that future regulatory decisions could significantly influence market perception.
Tickers: $QURE